MV BioTherapeutics SA

Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 7th Microbiome Movement – Drug Development Summit Europe 2023 being held in London during January 31st-February 2nd, 2023. The presentation has been included in the second day of the conference at 14.00. Reprogramming the Microbiome in Cancer Immunotherapy Outlining the adaptive modulation of the microbiota in dysbiosis by apyrase mediated secretory IgA amplification Exploring gut ecosystem proficiency in cancer immunotherapy by oral administration of apyrase

We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 5th Microbiome Movement – Drug Development Summit Europe 2021 being held virtually during January 27th-29th, 2021. The presentation has been included in the morning stream titled “Introducing the Era of Engineered Microbes” the 29th at 11.35. Leveraging Gut Microbiota Cross-Talk with Immune System to Enhance Cancer Immunotherapy Extracellular ATP (eATP) as a bacterial metabolite in host-microbiota mutualism Adaptive modulation of intestinal immunity by inhibition of eATP signalling Enhancement of immune checkpoint blockade by eATP interfering biotherapeutics “We were very glad and honored when the organizers contacted us and asked Fabio to participate and present the technology behind the company incorporation back in 2018” confirms Gabriel Haering, MV Bio CEO. “The gut microbiota continues to be the most unknown organ in our body. We discovered the function of eATP in host-microbiota mutualism and applied this knowledge to beneficially shape the gut ecosystem during cancer immunotherapy, thereby dramatically improving the therapeutic efficacy of immune checkpoint inhibitors” says Fabio Grassi, MV Bio founder and CSO. Additional details can be found on the event website microbiome-europe.com/ About MV BioTherapeutics MV BioTherapeutics is a Swiss microbiome biotherapeutics company founded in 2018 as a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona. The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections and to shape the intestinal microbiota in medical conditions with two applications: Research experiments and preclinical trials are performed in the research lab hosted at IRB.

MV BioTherapeutics participated for the first time to the international event Bio Digital 2020 presenting the company, the pipeline to over 50 companies. “We weren’t sure about the potential success when we applied to the Swiss Pavillon with the sponsoring of Innosuisse” confirms Dr. Fabio Grassi, founder and chairman. “The support we got from Switzerland Global Enterprise team prior to the meetings was really outstanding”. The 30 minutes meeting held were with very different companies. We met potential licensing partners for both our pharma and animal health application. Also an important contribution from CMOs and CROs that will be needed in the future moving forward into clinics. And last but no least some potential investors. The meetings confirmed that our Cancer Immunotherapy enhancer candidate (MV-002), with the latest enthusiastic results obtained, is getting the largest attention and interest. There are some discussions ongoing and our participation to the Bio Digital 2020 motivated us even more confirming that we are on the right track. MV BioTherapeutics was founded in 2018 as a spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona. The patent protected Apy platform is a unique mechanism to generate protective immune response against enteric infections. It shapes the intestinal microbiota in medical conditions with two applications: ApyraVax® is a technology platform for live attenuated oral vaccines eliciting protective mucosal responses against enteric pathogens. The first application is a vaccine for Clostridioides difficile infection. This is a disease that is causing hundreds of thousands of casualties every year and generating huge medical costs. ApyraMed® is a live biotherapeutic that has been validated in pre-clinical studies. It is an enhancer of immune checkpoint blockade in cancer immunotherapy and as a modulator of antibiotic-induced dysbiosis. is a technology platform for live attenuated oral vaccines eliciting protective mucosal responses against enteric pathogens. The first application is a vaccine for Clostridioides difficile infection. This is a disease that is causing hundreds of thousands of casualties every year and generating huge medical costs. is a live biotherapeutic that has been validated in pre-clinical studies. It is an enhancer of immune checkpoint blockade in cancer immunotherapy and as a modulator of antibiotic-induced dysbiosis. Research experiments and preclinical trials are performed in the research lab hosted at IRB. The company is looking for seed funding or strategic partnerships in order to move forward as a fully operational company into clinics.